Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Immunotherapy in Metastatic Melanoma
NCT01807182Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2013
- Primary completion
- Aug 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of Autologous tumor-infiltrating lymphocytes (MD Anderson) in melanoma, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Number of Participants in Each Clinical Response Category at 24 weeks. Started Aug 2013; status: completed.
02
Drugs
Autologous tumor-infiltrating lymphocytes (MD Anderson)
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01807182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01807182.